



A call for action to tackle the growing burden of dementia

From the member academies of IAP for Health



the interacademy partnership

Introduction

The proportion of the world's population that is 65 years of age or greater has grown over the last decades, and this trend will continue. Advancing age is the greatest known risk factor for dementia^{1, 2}. If there is no change in age-standardized prevalence, societal aging is predicted to nearly triple the number of individuals living with dementia worldwide by 2050^{3, 4}. It is estimated that, by 2050, the number of individuals with dementia will rise from 47.5 million people to an estimated 135.5 million with most of this increase occurring among people living in low- and middle-income countries². Aside from the personal cost of dementia, these rising numbers will be associated with an economic burden. The 2015 global estimated cost of dementia was US\$ 818 billion and is expected to be a trillion dollars by 2018⁵.

The World Health Organization (WHO) now recognizes dementia as a public health priority^{6, 7}. To respond to this challenge, a global series of actions initiated during the UK G8-Presidency in 2013 were undertaken by bodies such as the Organisation for Economic Cooperation and Development (OECD)⁸, Alzheimer's Disease International (ADI) and by the World Dementia Council⁹.

Dementia Overview

Dementia is an acquired, persisting and typically progressive decline in cognitive abilities, affecting learning and memory, language, and/or reasoning that are severe enough to interfere with independence in everyday activities. It becomes more common with increasing age during adulthood. Besides cognitive impairment, dementia is often associated with debilitating neuropsychiatric symptoms, such as agitation, psychosis, sleep disturbance, depression, anxiety and

apathy¹⁰. Dementia can arise from numerous conditions acting alone or in combination^{11, 12}. For many it is due to a neurodegenerative process, an umbrella term for a number of debilitating conditions that result in the progressive degeneration and/or death of neurons⁵. Alzheimer's disease is the most common neurodegenerative cause of dementia and is currently incurable. A mixture of brain diseases often underlies dementia, with many people showing changes consistent with both Alzheimer's and cerebrovascular disease^{13, 14}. Dementia is usually a slowly progressive illness where the diagnosis is made after the process has been present for years¹⁵.

Risk factors and conditions (such as smoking or diabetes) commonly associated with vascular conditions (stroke, heart disease) are also known to be associated with dementia^{16, 17}. Frailty itself is a considerable risk factor for dementia¹⁸. Likewise, Parkinson's disease is closely associated with the development of dementia¹⁹. The majority of older individuals with dementia have mixed pathology in their brain^{11, 12, 20, 21}.

While young onset (under 60 years) dementia is seen infrequently in many countries, this may not be the case in countries with high HIV prevalence. The HIV epidemic is concentrated in younger people of low-income countries, particularly in sub-Saharan Africa, where young people may subsequently bear a disproportionately greater burden of dementia²².

Women are at both greater risk of developing dementia and then living longer with the condition after its onset²³. Women also provide most of the informal (unpaid) care for people living with dementia. While there are currently no cures for the neurodegenerative conditions that lead to dementia, emerging research suggests that some life-style factors (e.g., engaging in physical activity, managing blood pressure, selected forms of cognitive training) may have the potential to delay, if not prevent, its onset²⁴⁻²⁷. Population studies have



suggested additional associated risk and protective factors, which require research to evaluate their potential as primary prevention intervention targets^{28, 29}. The progress to date in developing effective pharmacological treatment options has been disappointing³⁰⁻³², underscoring the need to understand better what contributes to the dementia syndrome in different generational cohorts as well as in different populations³³.

A key area for research and support is the development and dissemination of improvements for the care provided to people living with dementia including compassionate and appropriate end of life care³⁴⁻³⁷. Greater acceptance and inclusion of people living with dementia within communities is increasingly seen as an important factor in improving their quality of life and minimizing disability^{7, 38}. The needs of patients and their families change along the course of dementing illnesses and it is necessary to structure support and therapy for the different stages of the disease.

A Call to Action

Because of these issues, developing a comprehensive strategy internationally to address the challenges of dementia will require wide consultation followed by the long term implementation of a comprehensive, integrated and responsive series of actions. Most initiatives will be nationally based, but additional international collaborations to address dementia will also be advantageous. The nationally based initiatives will generally share similar high-level goals and principles to address this global health problem. We call for countries within regions that have resources to establish a network that can support other countries similar to them in their approach to dementia.

The goals and principles of a call to action would include addressing the following broad areas:

- Increasing public awareness – educating the general population about dementia, how to maintain brain health, and on the importance of addressing this health challenge, accepting people

with dementia as they are, and accommodating to their remaining abilities;

- Supporting research to find and implement effective approaches (both pharmacological and non-pharmacological) to delay, prevent, slow-down, treat, ameliorate, and eventually cure the common causes of dementia;
- Investing in national healthcare systems – this would entail both training a sufficient number and mix of providers as well as building the necessary infrastructure to ensure timely, competent person-centered care is available to those living with dementia and their caregivers through all stages of the illness.

Our Call to Action is one which aims at developing an evidence-based and a public health orientated approach. Ultimately, this should include a clear assessment for each population of the potential for primary prevention (upstream prevention), secondary prevention (early detection followed by effective treatment, considered to be likely more effective at that stage than later), and tertiary prevention (mitigation of dementia and its ramifications through various therapies and end of life care for those with dementia).

Elements of an Action Plan to Face the Challenge of Dementia

An action plan to face the challenge of dementia in its global context must include a concerted and coordinated series of actions from policies, to research, to care, to social inclusion. Such an action plan should include seven key elements:

1. National Dementia Plans must be established

National plans to combat dementia have been initiated in 29 countries/states since 2005. There is a global plan on dementia (<https://www.alz.co.uk/dementia-plans/global-plan>) being developed by the WHO^{6, 7} and the first regional plan on dementia in the Americas was published by the Pan American Health Organization (PAHO) in October 2015.

(See ADI website, <https://www.alz.co.uk/dementia-plans>, for a list of national plans currently under way, as well as countries currently lacking national plans). Canada is the only G7 country without a national dementia plan³⁹.

Each country should develop a national plan coherent with its healthcare goals which could coordinate activities, harmonize where appropriate with international efforts, promote the sharing of successful local initiatives, address identified gaps, ensure efficient use of resources, and mobilize further investment in all aspects of dementia including care and research. A national plan would acknowledge dementia as a public health priority and heighten awareness of this daunting health challenge.

As a first step towards such plans, we propose that a national dementia status report should be carried out in as many countries with resources as possible. Such a status report for each region would be wide-ranging, including information on the burden of all dementia types, comorbid disorders, risk factors, therapeutic approaches and care systems.

More research is necessary to establish the strength and interaction of lifecourse risk and protective factors relevant to dementia. Nevertheless, assessment of the 'exposome', potential risk and protective factors for each population, would be an important part of this report^{40, 41}. These reports should establish, for key lifestages, the balance in those populations of positive and negative features for brain health^{42, 43}. This would encompass a broad range of environmental factors such as maternal health, early life health, infections, education, vaccination, as well as adverse exposures such as poor housing, smoking, poor diet, and exposure to noxious substances.

A 5-year follow-up report should be planned to document the impact of national policies (public awareness, risk factors, care systems, etc.) and the creation of a national dementia strategy.


2. Increase investment in national research programmes on dementia

Investment in medical research varies widely across countries. In 2016, the American investment in dementia research was US\$ 936 million, which translates to US\$ 2.93 per capita²³. In contrast, the Canadian investment in research on dementia was smaller (less than a quarter per capita of what is invested in the USA)⁴⁴. Overall, developed countries do not adequately invest in dementia research when compared to the funding of research on other conditions such as cancer and heart disease, even though the cost of caring for persons with dementia is estimated to be greater than that for dealing with either of the other two conditions^{45, 46}. It has been stated that a goal of 1% of the national annual cost of dementia should be steered into dementia research programmes (Canadian Senate Report 2016 from Canada; ADI and WHO reports [2016]⁶). This additional investment in each country will have to be thoughtfully allocated and managed. Broad coordination within each country should be organized for best use of research funds. Governance and prioritization of dispersal of these funds must also involve individuals living with dementia and their caregivers, the research community, and practitioners.

3. Investment must span all aspects of dementia research

Allocated research funds should support a broad range of activity from biomedical investigation to inquiries dealing with clinical aspects, health systems and services research. In addition, research to gain better insight into understanding the social, cultural and environmental factors that affect the health of populations is essential. Investments should target national research capacity, supporting knowledge transfer, addressing the needs of unique populations (for example, indigenous people and those living in rural and remote communities⁴⁷⁻⁴⁹), investigating sex and gender differences in dementing conditions, and embracing ethical and social dimensions^{50, 51}.

There is now considerable potential for earlier diagnosis of various



forms of dementia using clinical, imaging and biomarker support⁵². The advantages and potential of early diagnosis is a critical focus of research in western countries⁵³⁻⁵⁷. Attention must now be paid to delineating the optimal approaches to early diagnosis and establishing the risks and benefits of translating this knowledge into healthcare policy.

The neuropsychiatric (behavioural and psychological) symptoms of dementia need more attention given their strong impact on quality of life, caregiver burden and rate of institutionalization^{10, 58, 59, 60}. Future research into the prevalence, aetiology and therapy (including randomized controlled trials) of neuropsychiatric symptoms of dementia is needed.

There must be research investment into understanding what combinations of modifiable lifestyle factors across the lifecourse increase and decrease the risk of developing dementia with aging^{26, 61}. This is not a one-size fits-all syndrome across the globe. The combinations of relevant risk factors may vary in different cultures and communities. The most effective preventative and public health strategy for dementia will only emerge when the fullest understanding of these factors is achieved.

Specific attention should be devoted to the support of social research aimed at identifying the actual needs of subjects with dementia and their caregivers⁶²⁻⁶⁴. The general purpose of such investigations would be the planning of multifaceted interventions encompassing environmental, psychological, medical and social support.

4. Risk reduction strategies should be instituted

While there is still a considerable amount to learn about the full interplay of risks, governments must support national risk-reduction and empowerment strategies for the public, and support the efforts of health professionals to promote healthy brain aging.

Current evidence can be used to empower the public and health professionals to act in ways that will reduce the risks of the development of all dementia types, postponing the appearance of their clinical manifestations, and optimizing everyday functioning in meaningful social activities and roles. The focus of such risk reduction would include vascular risk factors, obesity, diabetes, smoking, high-calorie diets, sleep problems, illiteracy, head trauma, malnutrition, and physical inactivity, in addition to other region-specific risk factors⁵.

Risk reduction at the individual level must be supplemented by evidence-based structural and legislative alterations that support these reductions. Smoking legislation, strategies for excessive alcohol risk reduction, reduction of dietary salt, and legislation to reduce head injuries are only a few of the risk reduction strategies that can be undertaken by governments to mitigate the occurrence of dementia in the population. Such governmental interventions will lead to less inequality because they benefit the disadvantaged as well. The Global Noncommunicable Disease Action Plan 2013-2020 focuses on many of these elements⁶.

5. The required workforce must be planned and trained

Workforce requirements to deal with the increasing number of persons with dementia must be determined and steps taken to ensure the required workforce is both trained and supported in their activities. A well trained and supported workforce of the right mix and number to deal with the needs of this emerging population is required. In each country, a national workforce plan will have to be created and implemented with the active involvement of local and regional authorities.

The full breadth of necessary trainees will only emerge after appropriate evidence-based strategies for risk reduction emerge. The workforce trained will initially be focused on the elderly and the healthcare sector, but addressing modifiable risks (for example, limited education and early childhood nutrition) implies an investment in teachers, nutritionists and a host of other professionals in the future.

6. Ensure that it is possible to live well with dementia

When a diagnosis of dementia is made, an individual should not be constrained to abandon her/his social role and participation. Creating the conditions within a country where one can live well with dementia includes ensuring that the public is aware of dementia in all its complexity, that there are accommodations in the environment (including work) to compensate for changing abilities, that there is adequate protection against abuses of all kinds against individuals living with dementia, and legal rights are not automatically withdrawn from people living with dementia. Cooperation between academies and local administrations should be encouraged so that all the needs of persons living with dementia and of their caregivers can be assessed and met.

7. Access to prevention and care should be made available to all

To the extent possible, access to preventive programmes, systems of care, and supportive living environments should be made available to all citizens with, or at risk of, dementia^{49, 65-67}.


The Future of the Dementia Challenge

Dementia will be part of the global landscape for many decades, reaching levels that are least twice the current values. Indeed, even if research could provide the means of eradicating brain diseases causing dementia tomorrow, numerous individuals would already be on the trajectory to dementia. Brain diseases causing dementia are now known to start many decades before any clinical signs are evident. For these reasons, a total solution will not be available for some time to come. This is why the member academies of IAP for Health are focusing attention on the necessity of engaging in an action plan for dementia which is balanced and designed to address all aspects of the challenge, especially the wellness of those living with dementia and their caregivers.



Bibliography

1. Prince M. *et al.* (2013). *Alzheimers Dement.* 9:63-75.
2. Prince M.J. *et al.* (2014). World Alzheimer Report 2014 - Dementia and risk reduction: An analysis of protective and modifiable factors.
3. Canadian Study of Health and Aging (1994). *Neurology* 44:2073-2080.
4. Ferri C.P. *et al.* (2005). *Lancet* 366:2112-2117.
5. Winblad B. *et al.* (2016). *Lancet Neurol.* 15:455-532.
6. World Health Organization (2013). Global action plan for the prevention and control of noncommunicable diseases 2013-2020.
7. World Health Organization (2017). WHO Global Network of Age-friendly Cities and Communities.
8. OECD (2014). Unleashing the Power of Big Data for Alzheimer's Disease and Dementia Research: OECD Publishing. <http://dx.doi.org/10.1787/5jz73kvmvbw-b-en>
9. Prince M. (2016). World Alzheimer Report 2016 - Improving healthcare for people living with dementia.
10. Jeste D.V. *et al.* (2006). *J. Geriatr. Psychiatry Neurol.* 19:160-171.
11. Schneider J.A. *et al.* (2009). *Ann. Neurol.* 66:200-208.
12. Schneider J.A. *et al.* (2009). *J. Alzheimers Dis.* 18:691-701.
13. Hachinski V. & Sposato L.A. (2013). *Brain* 136:2652-2654.
14. Hachinski V. (2008). *JAMA* 300:2172-2173.
15. Larson E.B. *et al.* (2013). *N. Engl. J. Med.* 369:2275-2277.
16. Black S. & Iadecola C. (2009). *Stroke* 40:S38-39.
17. Smith E. (2016). *Continuum (Minneapolis)* 22:490-509.
18. Song X. *et al.* (2014). *Alzheimers Res. Ther.* 6:54.
19. Huber S.J. (1989). *Archives of Neurology* 46:1287-1291.
20. Brayne C. *et al.* (2009). *J. Alzheimers Dis.* 18:645-658.
21. Richards M. & Brayne C. (2010). *BMJ* 341:c4670.
22. de-Graft Aikens A. *et al.* (2016). In: A. de-Graft Aikens & C. Agyemang (Eds), Chronic non-communicable diseases in low and middle income countries: a synthesis of research, interventions, and policies. Oxford: CABI Publishers: pp. 50-68.
23. Alzheimer's-Association (2015). *Alzheimer's & Dementia* 11:332-384.
24. Richards M. & Deary I.J. (2005). *Ann. Neurol.* 58:617-622.
25. Solomon A. *et al.* (2014). *J. Intern. Med.* 275:229-250.
26. Norton S. *et al.* (2014). *Lancet Neurol.* 13:788-794.
27. Ngandu T. *et al.* (2015). *Lancet* 385:2255-2263.
28. Kivipelto M. & Mangialasche F. (2014). *Nat. Rev. Neurol.* 10:552-553.
29. Kivipelto M. *et al.* (2017). *Lancet Neurol.* 16:338-339.
30. Mangialasche F. *et al.* (2010). *Lancet Neurol.* 9:702-716.
31. Doody R.S. *et al.* (2014). *N. Engl. J. Med.* 370:311-321.
32. Salloway S. *et al.* (2014). *N. Engl. J. Med.* 370:322-333.
33. Baumgart M. (2015). *Alzheimers Dement.* 11:718-726.
34. Welsh M.D. (2001). *Curr. Neurol. Neurosci. Rep.* 1:346-349.
35. Hughes J.C. (2015). *Curr. Opin. Psychiatry* 28:188-193.
36. Hogan D.B. (2007). *Alzheimer's & Dementia* 3:355-384.
37. Ebly E.M. (1999). *Dementia & Geriatric Cognitive Disorders* 10:541-548.
38. Chalmers J. (2014). Dementia Friendly City Initiative Halifax. Halifax NS: <http://legacycontent.halifax.ca/boardscom/access/documents/DementiaFriendlyCityAAC140317.pdf>
39. Patterson C. *et al.* (1999) *Mature Medicine* 219.
40. Fargo K.N. (2014). *Alzheimers Dement.* 10:S430-S452.
41. Maloney B. & Lahiri D.K. (2016). *Lancet Neurol.* 15:760-774.
42. Brayne C. (2014). *Lancet Neurol.* 13:532-534.
43. Clare L. *et al.* (2017). *PLoS Med.* 14:e1002259.
44. Alzheimer Society of Canada (2010). Rising Tide: The impact of dementia on Canadian society http://www.alzheimer.ca/sites/default/files/files/national/advocacy/asc_rising_tide_full_report_e.pdf.
45. Wimo A. *et al.* (2013). *Alzheimers Dement.* 9:1-11.
46. Wimo A. *et al.* (2017). *Alzheimers Dement.* 13:1-7.
47. Jacklin K.M. *et al.* (2013). *Canadian Journal of Public Health* 104:e39-e44.
48. Innes A. *et al.* (2011). *Maturitas* 68:34-46.
49. Morgan D. *et al.* (2011). *Maturitas* 68:17-33.
50. Gauthier S. *et al.* (2016). *Continuum (Minneapolis)* 22:615-618.
51. Gauthier S. *et al.* (2013). *Prog Neurobiol.* 110:102-113.
52. Leibing A. (2014). *Cult. Med. Psychiatry* 38:217-236.
53. Chertkow H. *et al.* (2007). *Alzheimer's & Dementia* 3:266-282.
54. Feldman H.H. *et al.* (2005). *Am. J. Geriatr. Psychiatry* 13:645-655.
55. Feldman H.H. *et al.* (2008). *Cmaj* 178:825-836.
56. Scheltens P. *et al.* (2016). *Lancet* 388:505-517.
57. Rossini P.M. *et al.* (2016). *J. Alzheimers Dis.* 53:1389-1393.
58. Herrmann N. & Lanctot K.L. (1997). *Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie* 42:51S-64S.
59. Herrmann N. *et al.* (2007). *Alzheimer's & Dementia* 3:385-397.
60. Peters M.E. *et al.* (2013). *Am. J. Geriatr. Psychiatry* 21:1116-1124.
61. Norton M.C. *et al.* (2012). *J. Am. Geriatr. Soc.* 60:405-412.
62. Brodaty H. & Donkin M. (2009). *Dialogues Clin. Neurosci.* 11:217-228.
63. Ory M.G. *et al.* (1999). *The Gerontologist* 39:177-185.
64. Karlawish J.H. *et al.* (2000). *Neurology* 55:1008-1014.
65. Dorsey E.R. *et al.* (2013). *Neurology* 80:1989-1996.
66. Evans D.A. *et al.* (2011). *Alzheimers Dement.* 7:110-123.
67. Leuzy A. & Gauthier S. (2012). *Expert. Rev. Neurother.* 12:557-567.





This statement is modified from a position paper that was initially commissioned by the Canadian Academy of Health Sciences, and written, approved and submitted by the Research Executive Committee (REC) of the Canadian Consortium on Neurodegeneration in Aging (CCNA).

Working group

- Dr. **Howard Chertkow**, Canada (Chair)
- Prof. **Ama de-Graft Aikins**, Ghana
- Dr. **Liaquat Ali**, Bangladesh
- Dr. **Laila Asmal**, South Africa
- Prof. **Hayrunnisa Bolay Belen**, Turkey
- Prof. **Carol Brayne**, United Kingdom
- Dr. **Josef Priller**, Germany
- Prof. **Lars Lannfelt**, Sweden
- Prof. **Alan Leshner**, USA
- Dr. **Ninoslav Mimica**, Croatia
- Prof. **Maryam Noroozian**, Iran
- Prof. **Adesola Ogunniyi**, Nigeria
- Prof. **Juha Rinne**, Finland
- Prof. **Paolo Maria Rossini**, Italy
- Dr. **Jonas Alex Morales Saute**, Brazil
- Dr. **Philip Scheltens**, Netherlands
- Dr. **Ales Stuchlik**, Czech Rep.

The InterAcademy Partnership for Health

IAP for Health is a component network of the InterAcademy Partnership.

Its membership comprises 78 academies of medicine or academies of science and engineering with strong medical sections.

IAP for Health is committed to improving health worldwide, including through the release of consensus statements on matters of importance to global health. IAP for Health Statements such as this one are prepared by a working group comprising experts nominated by member academies, and are released once they have been endorsed by more than half the member academies of the network.

Academies that endorsed the statement by 4 April 2018

- National Academy of Medicine, Argentina
- National Academy of Sciences of the Republic of Armenia
- Austrian Academy of Sciences
- Bangladesh Academy of Sciences
- *Académie Royale de Médecine de Belgique*
- Brazilian Academy of Sciences
- National Academy of Medicine of Brazil
- Cameroon Academy of Sciences
- Canadian Academy of Health Sciences
- Chinese Academy of Sciences
- Chinese Academy of Engineering
- *Academia Nacional de Medicina, Colombia*
- Croatian Academy of Medical Science
- Croatian Academy of Sciences and Arts
- Cuban Academy of Sciences
- Czech Academy of Sciences
- Council of Finnish Academies
- *Académie des Sciences, Institut de France*
- *Deutsche Akademie der Naturforscher Leopoldina*
- Union of the German Academies of Sciences and Humanities
- Academy of Athens, Greece
- Academy of Medical Physical and Natural Sciences of Guatemala
- Hungarian Academy of Sciences
- Indonesian Academy of Sciences
- *Accademia Nazionale dei Lincei, Italy*
- Science Council of Japan
- Kenya National Academy of Sciences
- Korean Academy of Science and Technology (KAST)
- National Academy of Sciences, Republic of Korea (KNAS)
- Academy of Sciences Malaysia
- Montenegrin Academy of Sciences and Arts
- Hassan II Academy of Science and Technology, Morocco
- Royal Netherlands Academy of Arts and Sciences (KNAW)
- Nigerian Academy of Sciences
- Palestine Academy for Science and Technology (PALAST)
- National Academy of Medicine, Peru
- National Academy of Science and Technology, Philippines
- Academy of Medical Sciences of Romania
- Academy of Science of South Africa (ASSAf)
- National Academy of Sciences of Sri Lanka
- Sudanese National Academy of Sciences
- Royal Swedish Academy of Sciences
- Swiss Academy of Medical Sciences
- Tanzania Academy of Sciences
- Thai Academy of Science and Technology (TAST)
- Turkish Academy of Sciences (TUBA)
- Uganda National Academy of Sciences (UNAS)
- Academy of Medical Sciences, UK
- National Academy of Medicine (NAM), US
- African Academy of Sciences
- Caribbean Academy of Sciences
- Islamic World Academy of Sciences (IAS)
- World Academy of Art and Science (WAAS)

Additional copies of this statement can be downloaded from:
<http://www.interacademies.org/45731/IAP-for-Health-A-call-for-action-to-tackle-the-growing-burden-of-dementia>.



the interacademy partnership

IAP for Health

ICTP Campus, Strada Costiera 11, 34151 Trieste, Italy

Tel. +39 040 22 40 681

E-mail: iap@twas.org

Url: www.interacademies.org